Danaher Corp /De/DHR
What Danaher Corp /De/ does.
Danaher is a global science and technology innovator committed to accelerating the power of science and technology to improve human health. Danaher is comprised of more than 15 operating companies with leadership positions in the biotechnology, life sciences and diagnostics sectors, organized under three segments (Biotechnology, Life Sciences and Diagnostics). United by the DANAHER BUSINESS SYSTEM (“DBS”), our businesses are also typically characterized by a high level of products and services that are sold on a recurring basis, primarily through a direct sales model and to a geographically diverse customer base. Our business’ research and development, manufacturing, sales, distribution, service and administrative facilities are located in approximately 50 countries.
Danaher measures its progress against these strategic priorities over the long-term based primarily on financial metrics relating to revenue growth, profitability, cash flow and capital returns, as well as certain non-financial metrics. To further the strategic objectives set forth above, the Company also acquires businesses and makes investments that either complement its existing business portfolio or expand its portfolio into new markets that the Company deems attractive. Given the rapid pace of technological development and the specialized expertise typical of Danaher’s served markets, acquisitions as well as strategic alliances and investments can provide the Company access to important new technologies and domain expertise, and Danaher continues to pursue acquisition and investment opportunities within its targeted markets. The extent to which we identify, consummate and effectively integrate appropriate acquisitions and consummate appropriate investments affects our overall growth and operating results. Danaher also continually assesses the strategic fit of its existing businesses and may separate or otherwise dispose of businesses based on strategic and other considerations.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $22.3B | $24.8B | $26.6B | $23.9B | $23.9B | $24.6B |
| Net income | $3.6B | $6.4B | $7.2B | $4.8B | $3.9B | $3.6B |
| Free cash flow | $5.4B | $7.1B | $7.4B | $5.8B | $5.3B | $5.3B |
More on DHR.
- Danaher Corp /De/ summary
- Danaher Corp /De/ financial statements
- Danaher Corp /De/ key metrics
- Danaher Corp /De/ health scores and style box
- Danaher Corp /De/ earnings
- Danaher Corp /De/ dividends
- Danaher Corp /De/ valuation
- Danaher Corp /De/ ownership and insiders
- Danaher Corp /De/ peers
Figures from Danaher Corp /De/'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.